We use cookies to ensure that we give you the best experience on our website. By continuing to browse this repository, you give consent for essential cookies to be used. You can read more about our Privacy and Cookie Policy.

Durham Research Online
You are in:

Copper(II)-bis(thiosemicarbazonato) complexes as antibacterial agents : insights into their mode of action and potential as therapeutics.

Djoko, Karrera Y. and Goytia, Maira M. and Donnelly, Paul S. and Schembri, Mark A. and Shafer, William M. and McEwan, Alastair G. (2015) 'Copper(II)-bis(thiosemicarbazonato) complexes as antibacterial agents : insights into their mode of action and potential as therapeutics.', Antimicrobial agents and chemotherapy., 59 (10). pp. 6444-6453.


There is increasing interest in the use of lipophilic copper (Cu)-containing complexes to combat bacterial infections. In this work, we showed that Cu complexes with bis(thiosemicarbazone) ligands [Cu(btsc)] exert antibacterial activity against a range of medically significant pathogens. Previous work using Neisseria gonorrhoeae showed that Cu(btsc) complexes may act as inhibitors of respiratory dehydrogenases in the electron transport chain. We now show that these complexes are also toxic against pathogens that lack a respiratory chain. Respiration in Escherichia coli was slightly affected by Cu(btsc) complexes, but our results indicate that, in this model bacterium, the complexes act primarily as agents that deliver toxic Cu ions efficiently into the cytoplasm. Although the chemistry of Cu(btsc) complexes may dictate their mechanism of action, their efficacy depends heavily on bacterial physiology. This is linked to the ability of the target bacterium to tolerate Cu and, additionally, the susceptibility of the respiratory chain to direct inhibition by Cu(btsc) complexes. The physiology of N. gonorrhoeae, including multidrug-resistant strains, makes it highly susceptible to damage by Cu ions and Cu(btsc) complexes, highlighting the potential of Cu(btsc) complexes (and Cu-based therapeutics) as a promising treatment against this important bacterial pathogen.

Item Type:Article
Full text:(AM) Accepted Manuscript
Download PDF
Publisher Web site:
Date accepted:23 July 2015
Date deposited:18 July 2018
Date of first online publication:03 August 2015
Date first made open access:No date available

Save or Share this output

Look up in GoogleScholar